Tempus AI (TEM) Stock Surges 24% on Merck and Moderna Cancer Vaccine Win
TLDR
- Tempus AI stock jumped nearly 24% after Merck and Moderna reported a Phase 3 win for their cancer vaccine
- The news boosted the value of Tempus AIโs $1.5 billion deal to acquire Personalis, which provides gene-sequencing tech for Modernaโs cancer program
- TEM reported its first-ever quarterly GAAP net profit of $5.6 million in Q2 2026, with revenue up 22% to $382.5 million
- Over 26% of TEMโs float is sold short, amplifying the upside move as short sellers rushed to cover
- Analysts hold a Moderate Buy consensus on TEM with an average price target of $62.15
Tempus AI stock is up nearly 24% on Wednesday, trading around $59.64, after Merck and Moderna announced a major Phase 3 success for their cancer vaccine program.
The news hit hard and fast. Tempus AI is in the process of acquiring Personalis for $1.5 billion. Personalis supplies the gene-sequencing technology that underpins Modernaโs cancer vaccine program. A successful Phase 3 trial makes that acquisition look a lot more valuable overnight.
โฆ Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
